HONOLULU — Tezepelumab improved outcomes among patients with severe, uncontrolled asthma regardless of BMI, according to an abstract presented at the CHEST Annual Meeting.
Geoffrey L. Chupp, MD, director of the Yale Center for Asthma and Airways Disease at Yale School of Medicine, and colleagues conducted a post-hoc analysis of data from the phase 3 NAVIGATOR study and the DESTINATION extension study, which included patients with severe, uncontrolled asthma, to assess annualized asthma exacerbation rate (AAER) over 104 weeks according to baseline BMI.
The patients who received 210 mg of